Transformative therapies against novel epigenetic targets
Epizyme is a commercial-stage biopharmaceutical company creating innovative drugs for major diseases based on epigenetics discoveries. It developed therapies targeting epigenetic targets for cancer and was acquired by Ipsen.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2019
Jul 2013
Oct 2009
Feb 2008
Create a free account to see which investors have funded this company.
Create Free Account
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
